Pheon Therapeutics, a U.K.- and Cambridge, Mass.-based startup developing treatments for a wide range of hard-to-treat cancers, emerged from stealth with $68 million in Series A funding. Brandon Capital, Forbion and Atlas Venture co-led the round, which included participation from Research Corporation Technologies. Jonathan Tobin, partner at Brandon Capital, was appointed chair of Pheon’s board.
Sudo Biosciences Inc., a Menlo Park, Calif.-based biopharmaceutical startup whose lead programs seek to treat immune-mediated inflammatory conditions, closed a $37 million Series A round led by Frazier Life Sciences and Velosity Capital.
Rippl, a mental health startup focused on caring for seniors with dementia and other neurocognitive conditions, launched with a $32 million seed investment. Led by ARCH Venture Partners and General Catalyst, the round included contributions from GV, F-Prime Capital and Mass General Brigham Ventures.
Form Bio Inc., a computational life sciences platform that spun out from Colossal Biosciences, launched with $30 million in Series A funding led by JAZZ Venture Partners. The company is based in Dallas and Austin.
XP Health Inc., a San Carlos, Calif.-based vision-care startup, raised a $17.1 million Series A round. HC9 Ventures, Valor Capital Group and ManchesterStory led the investment, which included additional support from Canvas Ventures, Cameron Ventures, Core Innovation Capital, GSR Ventures, Plug and Play and others.
careviso Inc., a Falls Church, Va.-based diagnostic testing technology provider, secured more than $17 million in Series B financing. Ballast Point Ventures led the round, which saw participation from Mercury Fund and Lytical Ventures.
Qnovia Inc., a Richmond, Va.-based startup developing inhaled therapeutics with an initial focus on nicotine replacement therapy, landed $17 million in Series A financing. Lead investor Blue Ledge Capital was joined by DG Ventures, Evolution VC Partners, Gaingels, TL Capital and Vice Ventures in the round.
Elucidata, a Cambridge, Mass.-based biomedical data platform, fetched $16 million in Series A funding. Led by Eight Roads Ventures, the round included participation from F-Prime Capital, IvyCap Ventures and Hyperplane Venture Capital.
Doccla, a London-based provider of virtual ward and patient monitoring technology, closed a £15 million Series A funding round. General Catalyst led the investment, with Managing Director Chris Bischoff joining the company’s board.
Optellum Ltd., a U.K.-based provider of an artificial intelligence platform to diagnose and treat early-stage lung cancer, collected $14 million in Series A funding. Mercia Asset Management led the investment, which saw participation from Intuitive Ventures, Black Opal Ventures, IQ Capital and others.
Cionic, a San Francisco-based bionic clothing startup, picked up $12.5 million in Series A financing. BlueRun Ventures led the round, which included support from Caffeinated Capital, EPIC Ventures, JobsOhio Growth Capital Fund and LDV Capital. BlueRun’s John Malloy will join the board.
DocSpera, an intelligent surgical planning platform, snagged a $10 million Series B round led by Pier 70 Ventures and Johnson & Johnson Innovation – JJDC Inc.
|